Prognostic significance of MGMT gene promoter methylation in differently treated metastatic melanomas

A. M. Cesinaro, G. Sartori, M. Migaldi, L. Schirosi, G. Pellacani, G. Collina, A. Maiorana

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Aims: The methylation status of the MGMT gene promoter, considered of prognostic significance by enhancing chemosensitivity to alkylating drugs in gliomas and melanomas, was evaluated in a series of primary melanomas and metastases of patients treated with different therapies, to identify any correlation with the patients' outcome or response to different therapeutic regimens. Methods: Twenty-nine primary melanomas and 74 metastases, collected from 52 patients, were assessed for MGMT gene promoter methylation using a standard methylation specific PCR-based method. All materials were formalin fixed and paraffin embedded. Results: One of 29 primary melanomas (3.4%) and 22 of 74 metastases (29.7%) showed MGMT gene promoter methylation. MGMT methylation was more frequent in visceral (17/40, 42.5%) than in cutaneous/lymph node metastases (5/34, 14.7%) (p= 0.019). Both disease free (DFS) and overall survival (OS) were significantly longer in patients with methylated metastases (p=0.009 and p=0.007, respectively). No correlations were found among methylation, therapeutic regimens and DFS or OS. Conclusions: MGMTmethylation appears to be a late event in the biological history of melanoma and is more frequently seen in visceral metastases. The MGMT gene promoter methylation in metastatic disease is associated with longer survival, irrespective of therapy. Thus it could be considered a prognostic factor in metastatic melanoma.

Original languageEnglish
Pages (from-to)313-317
Number of pages5
JournalPathology
Volume44
Issue number4
DOIs
Publication statusPublished - Jun 2012

Fingerprint

Methylation
Melanoma
Neoplasm Metastasis
Genes
Survival
Therapeutics
Glioma
Paraffin
Formaldehyde
Lymph Nodes
History
Polymerase Chain Reaction
Skin
Pharmaceutical Preparations

Keywords

  • Melanoma
  • Metastasis
  • Methylation
  • MGMT
  • Prognosis
  • Therapy

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Cesinaro, A. M., Sartori, G., Migaldi, M., Schirosi, L., Pellacani, G., Collina, G., & Maiorana, A. (2012). Prognostic significance of MGMT gene promoter methylation in differently treated metastatic melanomas. Pathology, 44(4), 313-317. https://doi.org/10.1097/PAT.0b013e328353a0ff

Prognostic significance of MGMT gene promoter methylation in differently treated metastatic melanomas. / Cesinaro, A. M.; Sartori, G.; Migaldi, M.; Schirosi, L.; Pellacani, G.; Collina, G.; Maiorana, A.

In: Pathology, Vol. 44, No. 4, 06.2012, p. 313-317.

Research output: Contribution to journalArticle

Cesinaro, AM, Sartori, G, Migaldi, M, Schirosi, L, Pellacani, G, Collina, G & Maiorana, A 2012, 'Prognostic significance of MGMT gene promoter methylation in differently treated metastatic melanomas', Pathology, vol. 44, no. 4, pp. 313-317. https://doi.org/10.1097/PAT.0b013e328353a0ff
Cesinaro AM, Sartori G, Migaldi M, Schirosi L, Pellacani G, Collina G et al. Prognostic significance of MGMT gene promoter methylation in differently treated metastatic melanomas. Pathology. 2012 Jun;44(4):313-317. https://doi.org/10.1097/PAT.0b013e328353a0ff
Cesinaro, A. M. ; Sartori, G. ; Migaldi, M. ; Schirosi, L. ; Pellacani, G. ; Collina, G. ; Maiorana, A. / Prognostic significance of MGMT gene promoter methylation in differently treated metastatic melanomas. In: Pathology. 2012 ; Vol. 44, No. 4. pp. 313-317.
@article{dea4abeb7b4949179f9eaf48a4efdb0e,
title = "Prognostic significance of MGMT gene promoter methylation in differently treated metastatic melanomas",
abstract = "Aims: The methylation status of the MGMT gene promoter, considered of prognostic significance by enhancing chemosensitivity to alkylating drugs in gliomas and melanomas, was evaluated in a series of primary melanomas and metastases of patients treated with different therapies, to identify any correlation with the patients' outcome or response to different therapeutic regimens. Methods: Twenty-nine primary melanomas and 74 metastases, collected from 52 patients, were assessed for MGMT gene promoter methylation using a standard methylation specific PCR-based method. All materials were formalin fixed and paraffin embedded. Results: One of 29 primary melanomas (3.4{\%}) and 22 of 74 metastases (29.7{\%}) showed MGMT gene promoter methylation. MGMT methylation was more frequent in visceral (17/40, 42.5{\%}) than in cutaneous/lymph node metastases (5/34, 14.7{\%}) (p= 0.019). Both disease free (DFS) and overall survival (OS) were significantly longer in patients with methylated metastases (p=0.009 and p=0.007, respectively). No correlations were found among methylation, therapeutic regimens and DFS or OS. Conclusions: MGMTmethylation appears to be a late event in the biological history of melanoma and is more frequently seen in visceral metastases. The MGMT gene promoter methylation in metastatic disease is associated with longer survival, irrespective of therapy. Thus it could be considered a prognostic factor in metastatic melanoma.",
keywords = "Melanoma, Metastasis, Methylation, MGMT, Prognosis, Therapy",
author = "Cesinaro, {A. M.} and G. Sartori and M. Migaldi and L. Schirosi and G. Pellacani and G. Collina and A. Maiorana",
year = "2012",
month = "6",
doi = "10.1097/PAT.0b013e328353a0ff",
language = "English",
volume = "44",
pages = "313--317",
journal = "Pathology",
issn = "0031-3025",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Prognostic significance of MGMT gene promoter methylation in differently treated metastatic melanomas

AU - Cesinaro, A. M.

AU - Sartori, G.

AU - Migaldi, M.

AU - Schirosi, L.

AU - Pellacani, G.

AU - Collina, G.

AU - Maiorana, A.

PY - 2012/6

Y1 - 2012/6

N2 - Aims: The methylation status of the MGMT gene promoter, considered of prognostic significance by enhancing chemosensitivity to alkylating drugs in gliomas and melanomas, was evaluated in a series of primary melanomas and metastases of patients treated with different therapies, to identify any correlation with the patients' outcome or response to different therapeutic regimens. Methods: Twenty-nine primary melanomas and 74 metastases, collected from 52 patients, were assessed for MGMT gene promoter methylation using a standard methylation specific PCR-based method. All materials were formalin fixed and paraffin embedded. Results: One of 29 primary melanomas (3.4%) and 22 of 74 metastases (29.7%) showed MGMT gene promoter methylation. MGMT methylation was more frequent in visceral (17/40, 42.5%) than in cutaneous/lymph node metastases (5/34, 14.7%) (p= 0.019). Both disease free (DFS) and overall survival (OS) were significantly longer in patients with methylated metastases (p=0.009 and p=0.007, respectively). No correlations were found among methylation, therapeutic regimens and DFS or OS. Conclusions: MGMTmethylation appears to be a late event in the biological history of melanoma and is more frequently seen in visceral metastases. The MGMT gene promoter methylation in metastatic disease is associated with longer survival, irrespective of therapy. Thus it could be considered a prognostic factor in metastatic melanoma.

AB - Aims: The methylation status of the MGMT gene promoter, considered of prognostic significance by enhancing chemosensitivity to alkylating drugs in gliomas and melanomas, was evaluated in a series of primary melanomas and metastases of patients treated with different therapies, to identify any correlation with the patients' outcome or response to different therapeutic regimens. Methods: Twenty-nine primary melanomas and 74 metastases, collected from 52 patients, were assessed for MGMT gene promoter methylation using a standard methylation specific PCR-based method. All materials were formalin fixed and paraffin embedded. Results: One of 29 primary melanomas (3.4%) and 22 of 74 metastases (29.7%) showed MGMT gene promoter methylation. MGMT methylation was more frequent in visceral (17/40, 42.5%) than in cutaneous/lymph node metastases (5/34, 14.7%) (p= 0.019). Both disease free (DFS) and overall survival (OS) were significantly longer in patients with methylated metastases (p=0.009 and p=0.007, respectively). No correlations were found among methylation, therapeutic regimens and DFS or OS. Conclusions: MGMTmethylation appears to be a late event in the biological history of melanoma and is more frequently seen in visceral metastases. The MGMT gene promoter methylation in metastatic disease is associated with longer survival, irrespective of therapy. Thus it could be considered a prognostic factor in metastatic melanoma.

KW - Melanoma

KW - Metastasis

KW - Methylation

KW - MGMT

KW - Prognosis

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84863651330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863651330&partnerID=8YFLogxK

U2 - 10.1097/PAT.0b013e328353a0ff

DO - 10.1097/PAT.0b013e328353a0ff

M3 - Article

VL - 44

SP - 313

EP - 317

JO - Pathology

JF - Pathology

SN - 0031-3025

IS - 4

ER -